权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A FUNCTIONAL CELL BASED ASSAY FOR SYNTHETIC CANNABINOIDS

基于功能细胞的合成大麻素测定

基本信息

批准号：
10261416
负责人：
Andrew Albert Monte
金额：
$ 19.22万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-15 至 2022-09-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10261416
关键词：
Accident and Emergency department Agonist Antibodies Arsenicals Binding Biological Assay Biosensor CNR1 gene CNR2 gene Cannabinoids Categories Cell Line Cell membrane Cells Cessation of life Chemicals Clinical Colorado Consumption Cyclic AMP Cyclic AMP Receptors Dangerousness Designer Drugs Detection Disease Outbreaks Drug Compounding Drug Screening Drug usage Enzymes Euphoria Evolution Exposure to Fluorescence Resonance Energy Transfer High Pressure Liquid Chromatography Human Immunoassay Ingestion Label Laboratories Law Enforcement Licensing Light Link Liquid Chromatography Mass Spectrum Analysis Measures Membrane Potentials Methods Molecular Molecular Conformation Opioid Receptor Optics Output Parents Patients Pharmaceutical Preparations Pharmacology Physical Dependence Potassium Channel Production Psychological Dependence Receptor Activation Receptor Cell Reference Standards Research Saline Sampling Schedule Signal Transduction System Techniques Testing Tetrahydrocannabinol Translating Universities Urine Work base bath salts cannabinoid receptor clinical effect cost detection method detection platform drug testing flexibility inhibitor/antagonist innovation liquid chromatography mass spectrometry novel therapeutics receptor rimonabant screening synthetic cannabinoid synthetic opioid virtual voltage sensitive dye

项目摘要

The overall objective of this proposal, A Functional Cell Based Assay for Synthetic Cannabinoids, is to develop a flexible and inexpensive screening assay that can detect all synthetic cannabinoids (SCs). Identification of SC abuse remains difficult for clinicians and law enforcement due to the rapid evolution of SC compounds. There are over 200 SCs known to exist though the most comprehensive clinical assay can only detect 43 of these drugs. In fact, more than 90% of SCs identified in patients seen in the University of Colorado Emergency Department are not detectable through the clinically available assay. High performance liquid chromatography- mass spectrometry methods are far more sensitive, though lack of reference standards, lack of availability, and cost remain a limitation of this drug detection method for the vast majority of clinical and law enforcement applications. New inexpensive drug screens able to detect rapidly evolving SC compounds are necessary. In this proposal, we employ an innovative strategy to detect new synthetic cannabinoids (SCs) through detection of activation of the cannabinoid receptor (CB1). The priorities are to create an assay that (a) will rapidly and cheaply detect binding and/or activation of CB1, (b) will distinguish between THC-level binding/activation and SC-level binding/activation, (c) can be integrated as a pre-screen prior to mass spectrometry confirmation. To achieve these priorities, we will develop and assess three independent detection systems of CB1 agonism via membrane potential change (Aim 1), cAMP production (Aim 2), and receptor conformational change (Aim 3). When completed, this receptor based-strategy can be used for detection of other new psychoactive substances, such as synthetic opioids, and can be optimized for rapid bedside screening of a large number of patients. Since avoidance of detection is a major reason SCs are chosen by users, increased screening will decrease use of these drugs. This technique is a solution for clinical and law enforcement detection of all new psychoactive substances.

本提案的总体目标，基于功能细胞的合成大麻素检测，是开发